Evidence map›Paper›PMID 29716540›Full record

SynthesisBMC cardiovascular disorders2018

Cost-of-illness studies in heart failure: a systematic review 2004-2016.

Wladimir Lesyuk, Christine Kriza, Peter Kolominsky-Rabas

3 registry-linked trialsOpen access · goldAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC cardiovascular disorders, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 213 papers, 22 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
213citing papers in PubMed, 22 pooled it
28.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05487365 naunknown statusnot on this mapstarted 2022, after this paper: background citation

Implementation and Cost-evaluation of a Smartphone-based Telemonitoring and Digital Support Platform in Patients With Heart Failure: the Bedicare-HF Multicentre Trial

TypeinterventionalSponsorComunicare Solutions SARan2022 to 2022Enrolled330ConditionsHeart Failure, Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class IVArmsComunicare Solutions Smartphone Application, Completing a quality of life (QOL)-questionnaire
NCT06795737 nanot yet recruitingnot on this mapstarted 2025, after this paper: background citation

Effectiveness and Safety of Exercise-based Cardiac Rehabilitation (ExCR) During the Vulnerable Period in Patients With Acute Decompensated Heart Failure (ADHF): A Randomized Controlled Trial

TypeinterventionalSponsorYE JingRan2025 to 2026Enrolled88ConditionsAcute Decompensated Heart Failure (ADHF)ArmsExercise rehabilitation, Conventional rehabilitation
NCT07403058 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

Endovascular Ablation Of The Right Greater Splanchnic Nerve In Subjects Having Heart Failure With Reduced Ejection Fraction: Randomized Controlled Feasibility Trial

TypeinterventionalSponsorAxon Therapies, Inc.Ran2026 to 2028Enrolled50ConditionsHeart Failure With Reduced Ejection Fraction (HFrEF)ArmsRight Greater Splanchnic Nerve (GSN) ablation, Sham Control
3 · Its place in the literature

Who cites it

213 citing papers in PubMed, 22 syntheses or guidelines pooled it, 441 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. The economic burden of Chagas disease: A systematic review.PLoS neglected tropical diseases · 2023
    Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Pooled it
  19. Pooled it
  20. Pooled it

153 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 2 countries.

Wladimir LesyukCentre for Health Technology Assessment (HTA) and Public Health (IZPH), Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany. wladimir.lesyuk@uk-erlangen.de.ORCID 0000-0002-2126-9143
Christine KrizaCentre for Health Technology Assessment (HTA) and Public Health (IZPH), Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
Peter Kolominsky-RabasCentre for Health Technology Assessment (HTA) and Public Health (IZPH), Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
Friedrich-Alexander-Universität Erlangen-Nürnberg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHeart failure is a major and growing medical and economic problem worldwide as 1-2% of the healthcare budget are spent for heart failure. The prevalence of heart failure has increased over the past decades and it is expected that there will be further raise due to the higher proportion of elderly in the western societies. In this context cost-of-illness studies can significantly contribute to a better understanding of the drivers and problems which lead to the increasing costs in heart failure. The aim of this study was to perform a systematic review of published cost-of-illness studies related to heart failure to highlight the increasing cost impact of heart failure.

methodsA systematic review was conducted from 2004 to 2016 to identify cost-of-illness studies related to heart failure, searching PubMed (Medline), Cochrane, Science Direct (Embase), Scopus and CRD York Database.

resultsOf the total of 16 studies identified, 11 studies reported prevalence-based estimates, 2 studies focused on incidence-based data and 3 articles presented both types of cost data. A large variation concerning cost components and estimates can be noted. Only three studies estimated indirect costs. Most of the included studies have shown that the costs for hospital admission are the most expensive cost element. Estimates for annual prevalence-based costs for heart failure patients range from $868 for South Korea to $25,532 for Germany. The lifetime costs for heart failure patients have been estimated to $126.819 per patient.

conclusionsOur review highlights the considerable and growing economic burden of heart failure on the health care systems. The cost-of-illness studies included in this review show large variations in methodology used and the cost results vary consequently. High quality data from cost-of-illness studies with a robust methodology applied can inform policy makers about the major cost drivers of heart failure and can be used as the basis of further economic evaluations.

Indexed as

Cost of IllnessHealth Care CostsCost-Benefit AnalysisHealthcare DisparitiesHeart FailureHospital CostsHumansIncidencePrevalenceTime FactorsTreatment OutcomeCost-of-illnessEconomic burdenHeart diseaseHeart failure

Identifiers

PMID29716540
PMCPMC5930493
OpenAlexW2799462148

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.